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Abstract
El Salvador harbours one of the largest Central American human immunodeﬁciency virus (HIV) epidemics, but few studies have analysed it
in depth. Here, we describe the presence of transmitted drug resistance (TDR) and HIV variants in the HIV-infected adult population in El
Salvador. Dried blood spots from 119 HIV-infected antiretroviral-naive adults attended in El Salvador were collected in 2011. The TDR was
assessed according to the list recommended by the WHO. HIV-1 variants were described using phylogeny. Pol sequences could be ampliﬁed
in 88 patients (50.6% men), with a mean age of 35 years. Almost all (96.7%) were infected with HIV through sexual practice and 58.7% were
recently diagnosed. The mean CD4+ count was 474 cells/mm3 and 43.1% and 15.5% of patients showed moderate (<500 CD4 cells) or
severe (<200) immune suppression, respectively. HIV-1 viral load was >100 000 copies/mL in 24.7% of patients and <2000 copies/mL in
9.1%. Five samples (5.7%) harboured any TDR mutation: 2.3% for nucleoside reverse transcriptase inhibitor (NRTI) and non-nucleoside
reverse transcriptase inhibitor (NNRTI), and 1.4% for protease inhibitor (PI). All showed only one TDR single-class resistance mutation:
M184I (two cases) for NRTI, K101E and K103N for NNRTI and L23I for PI. All viruses excepting one (URF_BG) belonged to subtype B. No
phylogenetic TDR networks were found. In conclusion, we report a TDR prevalence of 5.7% in El Salvador, lower than in other Central
American studies. Periodical studies are essential to monitor and prevent TDR emergence in low-income and middle-income regions. Also,
more efforts are needed to promote early diagnosis and prevention of infection in El Salvador.
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Abstract
People screened for human immunodeﬁciency virus (HIV) using rapid diagnostic tests (RDTs) in Africa remain generally unaware of their
status for hepatitis B (HBV) and hepatitis C (HCV) infections. We evaluated a two-step screening strategy in Burkina Faso, using both HIV
RDTs and Dried Blood Spot (DBS) assays to conﬁrm an HIV-positive test, and to test for HBV and HCV infections. HIV counselling and
point-of-care testing were performed at a voluntary counselling and testing centre with HBV, HCV status and HIV conﬁrmation using DBS
specimens, being assessed at a central laboratory. Serological testing on plasma was used as the reference standard assay to control for the
performance of DBS assays. Nineteen out of 218 participants included in the study were positive for HIV using RDTs. A fourth-generation
HIV ELISA and immunoblot assays on DBS conﬁrmed HIV status. Twenty-four out of 25 participants infected with HBV were found positive
for hepatitis B surface antigen (HBsAg) using DBS. One sample with a low HBsAg concentration on plasma was not detected on DBS. Five
participants tested positive for HCV antibodies were conﬁrmed positive with an immunoblot assay using DBS specimens. Laboratory results
were communicated within 7 days to participants with no loss to follow up of participants between the ﬁrst and second post-test
counselling sessions. In conclusion, DBS collection during HIV point-of-care testing enables screening and conﬁrmation of HBV, HCV and
HIV infections. Diagnosis using DBS may assist with implementation of national programmes for HBV, HCV and HIV screening and clinical
care in middle- to low-income countries.
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